GeneDx Holdings Past Earnings Performance
Past criteria checks 0/6
GeneDx Holdings has been growing earnings at an average annual rate of 0.4%, while the Healthcare industry saw earnings growing at 5.3% annually. Revenues have been growing at an average rate of 5.1% per year.
Key information
0.4%
Earnings growth rate
128.0%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 5.1% |
Return on equity | -40.8% |
Net Margin | -31.2% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results
Nov 01GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
Oct 30GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
Oct 21After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar
Oct 04Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
Aug 19Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher
Jul 27GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors
Jun 12GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
Jun 06Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13
Feb 23The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More
Feb 22Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified
Dec 20Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)
Nov 02Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%
Nov 01Sema4 names Kevin Feeley as CFO
Aug 26Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Aug 20Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 19Sema4 Q2 2022 Earnings Preview
Aug 12Sema4 Holdings, Big Data For Precision Medicine Solutions
Jul 18Revenue & Expenses Breakdown
How GeneDx Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 267 | -83 | 166 | 46 |
30 Jun 24 | 244 | -117 | 165 | 49 |
31 Mar 24 | 222 | -135 | 176 | 55 |
31 Dec 23 | 203 | -176 | 195 | 58 |
30 Sep 23 | 206 | -459 | 225 | 70 |
30 Jun 23 | 236 | -494 | 268 | 69 |
31 Mar 23 | 224 | -533 | 322 | 79 |
31 Dec 22 | 235 | -549 | 338 | 86 |
30 Sep 22 | 231 | -280 | 357 | 84 |
30 Jun 22 | 191 | -170 | 332 | 89 |
31 Mar 22 | 202 | -131 | 259 | 73 |
31 Dec 21 | 212 | -245 | 324 | 105 |
30 Sep 21 | 218 | -331 | 328 | 114 |
30 Jun 21 | 214 | -420 | 305 | 115 |
31 Mar 21 | 197 | -406 | 291 | 113 |
31 Dec 20 | 179 | -241 | 173 | 73 |
31 Dec 19 | 196 | -33 | 78 | 35 |
31 Dec 18 | 133 | -27 | 49 | 21 |
Quality Earnings: WGS is currently unprofitable.
Growing Profit Margin: WGS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WGS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.
Accelerating Growth: Unable to compare WGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WGS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).
Return on Equity
High ROE: WGS has a negative Return on Equity (-40.83%), as it is currently unprofitable.